|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
|
EP0216846B2
(en)
|
1985-04-01 |
1995-04-26 |
Celltech Limited |
Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
|
|
JPS62153300A
(ja)
|
1985-12-26 |
1987-07-08 |
Teijin Ltd |
ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法
|
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
US6174666B1
(en)
|
1992-03-27 |
2001-01-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of eliminating inhibitory/instability regions from mRNA
|
|
US5326856A
(en)
|
1992-04-09 |
1994-07-05 |
Cytogen Corporation |
Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
|
|
CA2118508A1
(en)
|
1992-04-24 |
1993-11-11 |
Elizabeth S. Ward |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
US5885573A
(en)
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
EP1658772A3
(en)
|
1995-01-17 |
2007-01-17 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
|
US6030613A
(en)
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
JP4046354B2
(ja)
|
1996-03-18 |
2008-02-13 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
増大した半減期を有する免疫グロブリン様ドメイン
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
PL209392B1
(pl)
|
1999-01-15 |
2011-08-31 |
Genentech Inc |
Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
HUP0204475A2
(en)
|
2000-02-11 |
2003-04-28 |
Merck Patent Gmbh |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
US6725230B2
(en)
|
2000-07-18 |
2004-04-20 |
Aegis Analytical Corporation |
System, method and computer program for assembling process data of multi-database origins using a hierarchical display
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
WO2002043658A2
(en)
|
2000-11-06 |
2002-06-06 |
The Jackson Laboratory |
Fcrn-based therapeutics for the treatment of auto-immune disorders
|
|
WO2002040047A2
(en)
|
2000-11-20 |
2002-05-23 |
Canadian Blood Services |
Method for treating thrombocytopenia with monoclonal ivig
|
|
US7658921B2
(en)
|
2000-12-12 |
2010-02-09 |
Medimmune, Llc |
Molecules with extended half-lives, compositions and uses thereof
|
|
US7083784B2
(en)
|
2000-12-12 |
2006-08-01 |
Medimmune, Inc. |
Molecules with extended half-lives, compositions and uses thereof
|
|
NZ571596A
(en)
|
2001-08-03 |
2010-11-26 |
Glycart Biotechnology Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
ATE483472T1
(de)
|
2002-05-30 |
2010-10-15 |
Macrogenics Inc |
Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
|
|
DK1534335T4
(en)
|
2002-08-14 |
2015-10-05 |
Macrogenics Inc |
FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
|
|
EP1553975B8
(en)
|
2002-09-27 |
2023-04-12 |
Xencor, Inc. |
Optimized fc variants and methods for their generation
|
|
DK1562972T3
(da)
|
2002-10-15 |
2010-12-06 |
Facet Biotech Corp |
Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
|
|
EP1588166A4
(en)
|
2003-01-09 |
2007-06-27 |
Macrogenics Inc |
VECTOR SYSTEM WITH DOUBLE EXPRESSION FOR EXPRESSING ANTIBODIES IN BACTERIAL AND MAMMAL CELLS
|
|
CA2512729C
(en)
|
2003-01-09 |
2014-09-16 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
|
CA2512974A1
(en)
|
2003-01-13 |
2004-07-29 |
Macrogenics, Inc. |
Soluble fc.gamma.r fusion proteins and methods of use thereof
|
|
DK2236154T3
(en)
|
2003-02-10 |
2018-06-25 |
Biogen Ma Inc |
IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT
|
|
US7662928B2
(en)
|
2003-08-08 |
2010-02-16 |
The Research Foundation Of State University Of New York |
Anti-FcRn antibodies for treatment of auto/allo immune conditions
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
WO2006028936A2
(en)
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
|
PA8661401A1
(es)
|
2005-01-28 |
2006-09-08 |
Wyeth Corp |
Formulaciones del liquido polipeptido estabilizado
|
|
CA2606378A1
(en)
|
2005-04-29 |
2006-11-09 |
The Jackson Laboratory |
Fcrn antibodies and uses thereof
|
|
US8188223B2
(en)
|
2005-05-18 |
2012-05-29 |
Ablynx N.V. |
Serum albumin binding proteins
|
|
WO2006130834A2
(en)
|
2005-05-31 |
2006-12-07 |
Board Of Regents, The University Of Texas System |
IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
|
|
TW200745163A
(en)
|
2006-02-17 |
2007-12-16 |
Syntonix Pharmaceuticals Inc |
Peptides that block the binding of IgG to FcRn
|
|
US20100034194A1
(en)
*
|
2006-10-11 |
2010-02-11 |
Siemens Communications Inc. |
Eliminating unreachable subscribers in voice-over-ip networks
|
|
EP2144930A1
(en)
|
2007-04-18 |
2010-01-20 |
ZymoGenetics, Inc. |
Single chain fc, methods of making and methods of treatment
|
|
EP2158318A2
(en)
|
2007-05-14 |
2010-03-03 |
Biogen Idec MA, Inc. |
Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
|
|
PL2185589T3
(pl)
|
2007-06-01 |
2016-09-30 |
|
Środki wiążące receptor regionu stałego Fc immunoglobuliny
|
|
US8935381B2
(en)
|
2007-11-27 |
2015-01-13 |
Zettics, Inc. |
Method and apparatus for real-time collection of information about application level activity and other user information on a mobile data network
|
|
US9260525B2
(en)
|
2008-02-04 |
2016-02-16 |
Xiao-Jia Chang |
Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
|
|
WO2009100105A2
(en)
|
2008-02-04 |
2009-08-13 |
Attogen Inc. |
Inhibitors of oncogenic isoforms and uses thereof
|
|
WO2009131702A2
(en)
|
2008-04-25 |
2009-10-29 |
Dyax Corp. |
Antibodies against fcrn and use thereof
|
|
WO2010014909A1
(en)
|
2008-08-01 |
2010-02-04 |
Syntonix Pharmaceuticals, Inc. |
Immunomodulatory peptides
|
|
EP2233500A1
(en)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Optimized Fc variants
|
|
NZ594343A
(en)
|
2009-03-25 |
2013-10-25 |
Genentech Inc |
Novel anti-alpha5beta1 antibodies and uses thereof
|
|
HUE028832T2
(en)
|
2009-09-17 |
2017-01-30 |
Baxalta Inc |
Stable co-formulation of hyaluronidase and immunoglobulin, as well as a process for its preparation
|
|
JP5898082B2
(ja)
|
2009-10-07 |
2016-04-06 |
マクロジェニクス，インコーポレーテッド |
フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法
|
|
BR112012013148A2
(pt)
|
2009-12-29 |
2017-03-21 |
F Hoffmann - La Roche Ag |
formulação farmacêutica e uso
|
|
TWI542597B
(zh)
|
2010-07-28 |
2016-07-21 |
吉林尼克公司 |
產生依序多聚體化免疫球蛋白ｆｃ組合物之天然人類蛋白質片段之融合蛋白
|
|
ES2765874T3
(es)
|
2011-05-25 |
2020-06-11 |
Innate Pharma Sa |
Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
|
|
AU2012262007B2
(en)
|
2011-06-02 |
2017-06-22 |
Takeda Pharmaceutical Company Limited |
Fc receptor binding proteins
|
|
EP2723771B1
(en)
|
2011-06-23 |
2019-09-11 |
Ablynx NV |
Serum albumin binding proteins
|
|
AU2012328819B2
(en)
|
2011-10-26 |
2017-08-03 |
Elanco Tiergesundheit Ag |
Monoclonal antibodies and methods of use
|
|
US20140302028A1
(en)
|
2011-11-18 |
2014-10-09 |
Merck Sharp & Dohme Corp. |
Fc containing polypeptides having increased anti-inflammatory properties and increased fcrn binding
|
|
KR102041412B1
(ko)
|
2011-12-30 |
2019-11-11 |
한미사이언스 주식회사 |
면역글로불린 Ｆｃ 단편 유도체
|
|
KR20150008171A
(ko)
*
|
2012-05-10 |
2015-01-21 |
자임워크스 인코포레이티드 |
단일군 일가 항체 구조물 및 그의 용도
|
|
GB201208370D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Antibodies
|
|
JP6285923B2
(ja)
|
2012-06-22 |
2018-02-28 |
トラスティーズ・オブ・ダートマス・カレッジ |
新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用
|
|
US9803191B2
(en)
|
2012-07-05 |
2017-10-31 |
Genentech, Inc. |
Expression and secretion system
|
|
CN104736174B
(zh)
|
2012-07-06 |
2019-06-14 |
根马布私人有限公司 |
具有三重突变的二聚体蛋白质
|
|
GB201302878D0
(en)
|
2013-02-19 |
2013-04-03 |
Argen X Bv |
Modified igG molecules
|
|
AU2014230018B2
(en)
|
2013-03-15 |
2018-02-22 |
Affibody Ab |
New polypeptides
|
|
KR101815265B1
(ko)
|
2013-06-20 |
2018-01-04 |
한올바이오파마주식회사 |
FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
|
|
CA2927592C
(en)
|
2013-10-28 |
2020-08-18 |
Ngm Biopharmaceuticals, Inc. |
Fgf-19 variants for treating a fgf-19 dependent cancer or tumor
|
|
GB201320066D0
(en)
|
2013-11-13 |
2013-12-25 |
Ucb Pharma Sa |
Biological products
|
|
JP2016538283A
(ja)
*
|
2013-11-13 |
2016-12-08 |
ザイムワークス，インコーポレイテッド |
Ｅｇｆｒ及び／またはｈｅｒ２を標的にする一価抗原結合性構築物及びその使用
|
|
WO2015081073A2
(en)
|
2013-11-26 |
2015-06-04 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods for modulating an immune response
|
|
SG11201605203UA
(en)
|
2013-12-24 |
2016-07-28 |
Argen X N V |
Fcrn antagonists and methods of use
|
|
PL3193930T3
(pl)
|
2014-09-17 |
2019-12-31 |
Affibody Ab |
Nowe polipeptydy
|
|
RS64768B1
(sr)
|
2015-01-30 |
2023-11-30 |
Momenta Pharmaceuticals Inc |
Fcrn antitela i načini njihove upotrebe
|
|
CA2978253A1
(en)
|
2015-03-09 |
2016-09-15 |
Argenx Bvba |
Methods of reducing serum levels of fc-containing agents using fcrn antagonists
|
|
EP3294335B1
(en)
|
2015-05-12 |
2023-07-05 |
Syntimmune Inc. |
Humanized affinity matured anti-fcrn antibodies
|
|
GB201508180D0
(en)
|
2015-05-13 |
2015-06-24 |
Ucb Biopharma Sprl |
Antibodies
|
|
EP3325004A1
(en)
|
2015-07-17 |
2018-05-30 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods and pharmaceutical compositions for inducing immune tolerance by mucosal vaccination with fc-coupled antigens
|
|
CN106957365B
(zh)
|
2016-01-11 |
2021-03-16 |
上海交通大学 |
一种单克隆抗体FnAb8及其应用
|
|
EP3448874A4
(en)
*
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
SMT202400004T1
(it)
|
2016-07-29 |
2024-03-13 |
Momenta Pharmaceuticals Inc |
Anticorpi fcrn e loro metodi di utilizzo
|
|
GB201618424D0
(en)
|
2016-11-01 |
2016-12-14 |
Argenix Bvba |
Treatment of antibody mediated disease
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
NZ759601A
(en)
|
2017-06-02 |
2023-06-30 |
Merck Patent Gmbh |
Aggrecan binding immunoglobulins
|
|
WO2018224439A1
(en)
*
|
2017-06-05 |
2018-12-13 |
Numab Innovation Ag |
Novel anti-hsa antibodies
|
|
CA3081144A1
(en)
*
|
2017-12-08 |
2019-06-13 |
Argenx Bvba |
Use of fcrn antagonists for treatment of generalized myasthenia gravis
|
|
KR102904658B1
(ko)
|
2017-12-13 |
2025-12-29 |
모멘타 파머슈티컬스 인코포레이티드 |
FcRn 항체 및 이의 사용 방법
|
|
US12202900B2
(en)
|
2018-06-08 |
2025-01-21 |
argenx BV |
Compositions and methods for treating immune thrombocytopenia
|
|
WO2020078905A1
(en)
*
|
2018-10-15 |
2020-04-23 |
Merck Patent Gmbh |
Combination therapy utilizing dna alkylating agents and atr inhibitors
|
|
KR102886990B1
(ko)
|
2018-11-06 |
2025-11-17 |
이뮤노반트 사이언시스 게엠베하 |
항-FcRn 항체를 이용한 그레이브스 안병증의 치료 방법
|
|
GB2589049C
(en)
|
2019-04-11 |
2024-02-21 |
argenx BV |
Anti-IgE antibodies
|
|
US20240124889A1
(en)
*
|
2019-05-07 |
2024-04-18 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
EP3969125A4
(en)
|
2019-05-17 |
2023-01-11 |
Alexion Pharmaceuticals, Inc. |
USE OF ANTI-FCRN ANTIBODIES IN THE TREATMENT OF PEMPHIGHUS AND PEMPHIGOID DISEASES
|
|
JP7565951B2
(ja)
|
2019-06-07 |
2024-10-11 |
アルジェニクス ビーブイ |
皮下投与に好適なＦｃＲｎインヒビターの医薬製剤
|
|
EP4007605A4
(en)
|
2019-08-01 |
2023-08-16 |
Momenta Pharmaceuticals, Inc. |
ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF
|
|
JP2023509195A
(ja)
|
2020-01-08 |
2023-03-07 |
アルジェニクス ビーブイ |
天疱瘡症を治療する方法
|
|
EP4139362A2
(en)
*
|
2020-04-22 |
2023-03-01 |
IGM Biosciences Inc. |
Pd-1 agonist multimeric binding molecules
|
|
IL302516A
(en)
|
2020-11-06 |
2023-07-01 |
Janssen Biotech Inc |
FCRN antibodies and methods of using them
|
|
KR20240040104A
(ko)
|
2021-08-02 |
2024-03-27 |
아르젠엑스 비브이 |
피하 단위 투여 형태
|
|
KR20240134900A
(ko)
|
2022-01-17 |
2024-09-10 |
아르젠엑스 비브이 |
자가항체 매개 질환 환자를 치료하기 위한 방법
|
|
MX2024010165A
(es)
|
2022-02-21 |
2024-08-27 |
argenx BV |
Metodos para tratar la miositis mediante el uso de antagonistas de fcrn.
|
|
CN119365209A
(zh)
|
2022-04-26 |
2025-01-24 |
阿根思有限公司 |
用于使用fcrn拮抗剂治疗大疱性类天疱疮的方法
|
|
CN119698429A
(zh)
|
2022-06-15 |
2025-03-25 |
阿根思有限公司 |
Fcrn结合分子及使用方法
|
|
US20230407243A1
(en)
|
2022-06-15 |
2023-12-21 |
University Of Guelph |
Genetic platform to investigate the functions of bacterial drug efflux pumps
|
|
EP4584295A1
(en)
|
2022-09-06 |
2025-07-16 |
Immunovant Sciences GmbH |
Methods of treating chronic inflammatory demyelinating polyneuropathy using anti-fcrn antibodies
|
|
TW202421195A
(zh)
|
2022-11-07 |
2024-06-01 |
比利時商阿根思公司 |
使用ｆｃｒｎ拮抗劑治療狼瘡性腎炎之方法
|
|
AR130995A1
(es)
|
2022-11-07 |
2025-02-05 |
argenx BV |
Métodos para el tratamiento de nefropatías membranosas primarias mediante el uso de antagonistas de fcrn
|
|
CN120344557A
(zh)
|
2022-11-14 |
2025-07-18 |
阿根思有限公司 |
Fcrn拮抗剂分子及其使用方法
|
|
AR131560A1
(es)
|
2023-01-06 |
2025-04-09 |
argenx BV |
Métodos para tratar pots mediante el uso de antagonistas de fcrn
|
|
CN120659623A
(zh)
|
2023-01-12 |
2025-09-16 |
阿根思有限公司 |
用于使用fcrn拮抗剂治疗原发性干燥综合征的方法
|
|
TW202448926A
(zh)
|
2023-02-17 |
2024-12-16 |
比利時商艾伯霖克斯公司 |
結合新生兒fc受體之多肽
|
|
WO2024189430A1
(en)
|
2023-03-14 |
2024-09-19 |
argenx BV |
Methods for vaccination of a subject treated with an fcrn antagonist
|
|
AU2024242538A1
(en)
|
2023-03-24 |
2025-10-30 |
Paragon Therapeutics, Inc. |
Fc fragments that bind fcrn and methods of use
|
|
IL325970A
(en)
|
2023-07-16 |
2026-03-01 |
argenx BV |
Methods for treating chronic inflammatory demyelinating neuropathy
|
|
US20250101111A1
(en)
|
2023-09-07 |
2025-03-27 |
argenx BV |
Fcrn antagonists and methods of use
|
|
GB202318512D0
(en)
|
2023-12-04 |
2024-01-17 |
argenx BV |
Methods of determining potency
|
|
WO2025133694A1
(en)
|
2023-12-20 |
2025-06-26 |
argenx BV |
Fcrn/hsa-binding molecules and methods of use
|
|
WO2025202714A1
(en)
|
2024-03-26 |
2025-10-02 |
argenx BV |
Methods for treating primary sjogren's syndrome using fcrn antagonists
|